Showing 3711-3720 of 7034 results for "".
- FDA Approves UCB’s BIMZELX for the Treatment of Adults with Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-ucbs-bimzelx-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis/2462079/The U.S. Food and Drug Administration (FDA) has approved BIMZELX (bimekizumab-bkzx) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Bimekizumab is the first and only approved psoriasis treatment desi
- Potential Eczema Breakthrough: IL-31 Feedback Loop Causes the Urge to Itch and Cools Nearby Inflammationhttps://practicaldermatology.com/news/potential-eczema-breakthrough-il-31-feedback-loop-causes-the-urge-to-itch-and-cools-nearby-inflammation/2462077/In a breakthrough that could transform how doctors treat conditions from eczema to allergies, scientists at UC San Francisco (UCSF) have discovered a feedback loop centered on a single immune protein called IL-31 that causes the urge to itch and dials back nearby inflammation.
- IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanomahttps://practicaldermatology.com/news/ideaya-biosciences-announces-phase-2-expansion-of-darovasertib-and-crizotinib-combination-in-gnaq11-metastatic-cutaneous-melanoma/2462076/IDEAYA Biosciences, Inc. is initiating of a Phase 2 expansion of the darovasertib and crizotinib combination in GNAQ/11 metastatic cutaneous melanoma. There are currently no U.S Food and Drug Administration-approved therapies for this genetically-defined patient population. Darova
- FDA Approves BMS’ Opdivo (Nivolumab) for Adjuvant Treatment of Eligible Patients with Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/fda-approves-bms-opdivo-nivolumab-for-adjuvant-treatment-of-eligible-patients-with-completely-resected-stage-iib-or-iic-melanoma/2462074/The U.S. Food and Drug Administration (FDA) has given its nod to Opdivo (nivolumab) for the adjuvant treatment of eligible adult and pediatric patients 12 years and older with completely resected stage IIB or IIC melanoma. This approval was based on the Phase 3
- AI in Action: Newest AI Boasts 100% Success Rate in Spotting Melanomashttps://practicaldermatology.com/news/newest-ai-boasts-100-success-rate-in-spotting-melanomas/2462072/The latest artificial intelligence (AI) software reached a 100% detection rate for melanoma, according to research presented at the European Academy of Dermatology and Venereology (EADV) Congress in Berlin. The study assessed 22,356 patients with suspected skin cancers over a 2.5-year p
- EADV News: Bimekizumab Achieves High Thresholds of Clinical Response in HShttps://practicaldermatology.com/news/eadv-news-bimekizumab-achieves-high-thresholds-of-clinical-response-in-hs/2462067/UCB’s Bimekizumab treatment results in clinically meaningful improvements in Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) and the more stringent HiSCR75, HiSCR90 and HiSCR100 compared with placebo at Week 16, with improvements increasing for patients remaining in the study t
- EADV News: Almirall’s Ilumetri Improves Well-being of Pso Patients and Their Familieshttps://practicaldermatology.com/news/eadv-news-almiralls-ilumetri-improves-well-being-of-pso-patients-and-their-families/2462056/Ilumetri (tildrakizumab) significantly improves the well-being of psoriasis patients and their relatives, according to new data presented at the European Association of Dermatology and Venereology Congress 2023. Interim data from the POSITIVE study showed that tildrakizumab significantl
- Protagonist Therapeutics JNJ-2113 Update: IL23-Blocker Advances Into Multiple Clinical Development Programs for PsO, UChttps://practicaldermatology.com/news/jnj-2113-update-il23-blocker-advances-into-multple-clinical-development-programs-for-pso-uc/2462054/Protagonist Therapeutics, Inc. will be eligible to receive $60 million in milestone payments in the fourth quarter for the advancement of JNJ-2113 (formerly known as PN-235) into multiple clinical development programs led by Janssen Biotech, Inc., a Johnson & Johnson company (Janssen), the Co
- Regenerative Medicine Breakthrough: Researchers Create BioPrinted Full Thickness Skinhttps://practicaldermatology.com/news/regenerative-medicine-breakthrough-researchers-create-bioprinted-full-thickness-skin/2462041/New bioprinted skin may accelerate wound healing, support healthy extracellular matrix remodeling, and aid in complete wound recovery, according to research out of the Wake Forest Institute for Regenerative Medicine (WFIRM). Available grafts are often temporary, or if permanent, h
- Measuring ctDNA May Lead to Alternative Treatment Options and Better Outcomes in Advanced Melanomahttps://practicaldermatology.com/news/measuring-ctdna-may-lead-to-alternative-treatment-options-and-better-outcomes-in-advanced-melanoma/2462040/Circulating tumor DNA (ctDNA) is emerging as a blood-based biomarker for many solid tumor types, including melanoma. A new study found that measuring ctDNA in the blood of patients with BRAF wild-type (BRAF WT) s